Antibody Therapy in Oncology
- 26 March 2014
- book chapter
- Published by Springer Nature
- p. 101-110
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal AdenocarcinomaClinical Cancer Research, 2013
- Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivoProceedings of the National Academy of Sciences, 2013
- Antibody Therapeutics in CancerScience, 2013
- Novel antibodies targeting immune regulatory checkpoints for cancer therapyBritish Journal of Clinical Pharmacology, 2013
- FcγRΙΙB controls the potency of agonistic anti-TNFR mAbsCancer Immunology, Immunotherapy, 2013
- Antibody therapy of cancerNature Reviews Cancer, 2012
- Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional PolymorphismClinical Cancer Research, 2004
- Rejection of Disseminated Metastases of Colon Carcinoma by Synergism of IL-12 Gene Therapy and 4-1BB CostimulationMolecular Therapy, 2000
- The CAMPATH‐1 antigen (CDw52)Tissue Antigens, 1990
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975